Nuances to precision dosing strategies of targeted cancer medicines. Issue 4 (13th July 2020)

• Record Type: Journal Article
• Authors: Hopkins, Ashley M.; Menz, Bradley D.; Wiese, Michael D.; Kichenadasse, Ganessan; Gurney, Howard; McKinnon, Ross A.; Rowland, Andrew; Sorich, Michael J.
• Is Part Of: Pharmacology research & perspectives. Volume 8:Issue 4(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-07-13
• Subjects: initial dose selection -- on‐therapy dose adaptation -- precision dosing -- prospective studies -- targeted cancer medicines; Pharmacology -- Periodicals; Drug development -- Periodicals; 615.105
• DOI: 10.1002/prp2.625
• Languages: English
• ISSNs: 2052-1707

Abstract

Abstract: Selecting the dose of a targeted cancer medicine that is most appropriate for a specific individual is a rational approach to maximize therapeutic outcomes and minimize toxicity. There are many different options for optimizing the dose of targeted cancer medicines and the purpose of this review is to provide a comprehensive comparison of the main options explored in prospective studies. Precision initial dose selection of targeted cancer therapies has been minimally explored to date; however, concentration, toxicity, and therapeutic outcome markers are used to guide on‐therapy dose adaption of targeted cancer therapies across several medicines and cancers. While a specific concentration, toxicity, or therapeutic outcome marker commonly dominates an investigated precision on‐therapy dose adaption strategy, greater attention to simultaneously account for exposure, toxicity, therapeutic outcomes, disease status, time since treatment initiation and patient preferences are required for optimal patient outcomes. To enable successful implementation of precision dosing strategies for targeted cancer medicines into clinical practice, future prospective studies aiming to develop strategies should consider these elements in their design.